Skip to main content

Magnesium citrate/melatonin Disease Interactions

There are 6 disease interactions with magnesium citrate / melatonin.

Major

Anxiolytics/sedatives/hypnotics (applies to magnesium citrate/melatonin) depression

Major Potential Hazard, Moderate plausibility.

A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of most anxiolytics, sedatives and hypnotics. Some of these changes include decreased inhibition, aggressiveness, agitation, and hallucinations. These drugs can cause or exacerbate mental depression and cause suicidal behavior and ideation. Therapy with these drugs should be administered cautiously in patients with a history of depression or other psychiatric disorders. Patients should be monitored for any changes in mood or behavior. It may be prudent to refrain from dispensing large quantities of medication to these patients.

References

  1. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb (2002):
  2. "Product Information. Ambien (zolpidem)." sanofi-aventis (2001):
  3. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical (2001):
  4. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc (2001):
  5. "Product Information. Equanil (meprobamate)." Wallace Laboratories (2001):
  6. "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories (2001):
  7. "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical (2001):
  8. "Product Information. Xyrem (sodium oxybate)." Orphan Medical (2002):
  9. "Product Information. Lunesta (eszopiclone)." Sepracor Inc (2004):
  10. "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America (2005):
  11. "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals (2010):
  12. "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group (2013):
  13. "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc (2014):
  14. "Product Information. Belsomra (suvorexant)." Merck & Company Inc (2014):
View all 14 references
Major

Laxatives (applies to magnesium citrate/melatonin) inflammatory bowel disease

Major Potential Hazard, Moderate plausibility.

The use of laxatives is contraindicated in patients with inflammatory bowel disease. Patients with inflammatory bowel disease may experience colonic perforation with use of stimulant laxatives.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc (2001):
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  4. "Product Information. Neoloid (castor oil)." Paddock Laboratories Inc (2001):
  5. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  6. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 6 references
Major

Laxatives (applies to magnesium citrate/melatonin) intestinal obstruction disorders

Major Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

The use of laxatives is contraindicated in patients with intestinal obstruction disorders. Patients with intestinal obstruction disorders may need their underlying condition treated to correct the constipation. Some laxatives require reduction in the colon to their active form to be effective which may be a problem in patients with intestinal obstruction.

References

  1. "Product Information. Dulcolax (bisacodyl)." Ciba Self-Medication Inc (2001):
  2. "Product Information. Fleet Bisacodyl Enema (bisacodyl)." Fleet, Lynchburg, VA.
  3. "Product Information. Kondremul (mineral oil)." Bristol-Myers Squibb, Princeton, NJ.
  4. "Product Information. Fleet Mineral Oil Enema (mineral oil)." Fleet (2001):
  5. "Product Information. Citrucel (methylcellulose)." SmithKline Beecham (2001):
  6. "Product Information. Fleet Babylax (glycerin)." Alcon Laboratories Inc (2001):
  7. "Product Information. SenoSol-X (senna)." Apothecon Inc (2022):
  8. "Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates)." Braintree Laboratories (2010):
View all 8 references
Major

Magnesium salts (applies to magnesium citrate/melatonin) renal dysfunction

Major Potential Hazard, High plausibility.

Magnesium is eliminated by the kidney. The serum concentration of magnesium is increased in patients with renal impairment. Magnesium toxicity includes CNS depression, muscular paralysis, respiratory depression, hypotension and prolonged cardiac conduction time. Disappearance of the patellar reflex is a useful clinical sign of magnesium intoxication. Therapy with magnesium should be administered cautiously and dosages should be modified in patients with compromised renal function. Clinical monitoring of serum magnesium levels is recommended.

References

  1. "Product Information. Mag-Ox 400 (magnesium oxide)." Blaine Company Inc. (2001):
  2. "Product Information. Uro-Mag (magnesium oxide)." Blaine Company Inc. (2001):
  3. "Product Information. Slow-Mag (magnesium chloride)." Searle (2001):
  4. "Product Information. Magonate (magnesium gluconate)." Fleming and Company (2001):
  5. "Product Information. Losospan (magaldrate)." Whitehall-Robbins (2001):
View all 5 references
Moderate

Anxiolytics/sedatives/hypnotics (applies to magnesium citrate/melatonin) glaucoma

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension, Urinary Retention

Some hypnotic drugs can have an anticholinergic effect and should be used with caution in patients with glaucoma, and trouble urinating due to retention or enlarged prostate.

References

  1. "Product Information. Benadryl (diphenhydramine)." Parke-Davis (2002):
  2. "Product Information. Unisom (doxylamine)." Pfizer U.S. Pharmaceuticals Group (2013):
Moderate

Anxiolytics/sedatives/hypnotics (applies to magnesium citrate/melatonin) liver disease

Moderate Potential Hazard, Moderate plausibility.

In general, anxiolytics, sedatives and hypnotics are extensively metabolized by the liver. Their plasma clearance may be decreased and their half-life prolonged in patients with impaired hepatic function. Therapy with these drugs should be administered cautiously in patients with liver disease (some are not recommended in severe liver impairment), and the dosage should be adjusted accordingly. Laboratory testing is recommended prior and during treatment.

References

  1. "Product Information. Buspar (buspirone)." Bristol-Myers Squibb (2002):
  2. "Product Information. Placidyl (ethchlorvynol)." Abbott Pharmaceutical (2001):
  3. "Product Information. Aquachloral Supprettes (chloral hydrate)." Medisca Inc (2001):
  4. "Product Information. Equanil (meprobamate)." Wallace Laboratories (2001):
  5. "Product Information. Sonata (zaleplon)." Wyeth-Ayerst Laboratories (2001):
  6. "Product Information. Precedex (dexmedetomidine)." Abbott Pharmaceutical (2001):
  7. "Product Information. Xyrem (sodium oxybate)." Orphan Medical (2002):
  8. "Product Information. Lunesta (eszopiclone)." Sepracor Inc (2004):
  9. "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America (2005):
  10. "Product Information. Silenor (doxepin)." Somaxon Pharmaceuticals (2010):
  11. "Product Information. Intermezzo (zolpidem)." Purdue Pharma LP (2011):
  12. "Product Information. Hetlioz (tasimelteon)." Vanda Pharmaceuticals Inc (2014):
  13. "Product Information. Belsomra (suvorexant)." Merck & Company Inc (2014):
View all 13 references

Magnesium citrate/melatonin drug interactions

There are 471 drug interactions with magnesium citrate / melatonin.

Magnesium citrate/melatonin alcohol/food interactions

There are 2 alcohol/food interactions with magnesium citrate / melatonin.


Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.